---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-093694"
form_type: "8-K"
ticker: "INVA"
cik: "0001080014"
company_name: "Innoviva, Inc."
filed_at: "2022-08-23T23:59:59+00:00"
generated_at: "2026-06-23T21:53:40.044488+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "low"
source: SEC EDGAR
---

# Innoviva files risk factor update with no specific new disclosure

## Summary
- Filed an 8-K to supplement risk factors from its June 30, 2022 10-Q and 2021 10-K.
- Updated risk factors cover clinical trial failure, patient enrollment delays, and third-party dependence.
- No specific new events, financial results, or business developments were reported.
- The risk factor language is standard biotech boilerplate with no material changes.

## SEC filing metadata
- accession: 0001104659-22-093694
- form_type: 8-K
- ticker: INVA
- cik: 0001080014
- company_name: Innoviva, Inc.
- filed_at: 2022-08-23T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: low
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1080014/000110465922093694/0001104659-22-093694-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1080014/000110465922093694/tm2224315d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-093694
- JSON: https://secwatch.observer/filing/0001104659-22-093694.json
- Plain text: https://secwatch.observer/filing/0001104659-22-093694.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.